Liquidia reported preliminary 2025 net product sales for Yutrepia totaling $148.3 million, with an outsized $90.1 million earned in the fourth quarter alone. This performance underscores rapid market uptake since FDA approval in May 2025 for pulmonary arterial hypertension (PAH) and PAH with interstitial lung disease (PH-ILD). Investors responded by lifting shares nearly 13% on Friday, reflecting confidence in the drug’s initial commercial momentum.

The strong fourth-quarter contribution translated into over $30 million of positive operating cash flow, boosting Liquidia’s cash and cash equivalents to approximately $190.7 million at year-end 2025. This liquidity cushion provides runway for ongoing launch support, potential label expansions and development of the company’s late-stage pipeline, while mitigating near-term dilution risks.

Management outlined plans to advance clinical programs for both Yutrepia and its extended-release treprostinil candidate L606 across current and future indications, aiming to enhance product differentiation through superior tolerability, higher achievable dosing and more rapid titration versus competing therapies. However, a looming intellectual property dispute with United Therapeutics presents binary risk; an adverse ruling could affect market exclusivity and valuation, even as commercial uptake remains robust.